A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by stimulating the mother’s body’s defences to produce protective antibodies, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, exactly when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst observing that protection can still occur even if given later in the third trimester.
- Nearly 85% protection when vaccinated 4 weeks before birth
- Antibodies from the mother passed through the placenta safeguard newborns from day one
- Coverage achievable with two-week gap before early delivery
- Vaccination in the third trimester still provides meaningful infant protection
Persuasive evidence from the latest research
The effectiveness of the RSV vaccine administered during pregnancy has been established through a comprehensive study carried out throughout England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that half-year window, providing robust and representative evidence of the vaccine’s actual performance. The study’s results have been validated by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scale of this research provides healthcare professionals and prospective parents with trust in the vaccine’s proven efficacy across different groups and contexts.
The results paint a notable picture of the vaccine’s protective power. More than 4,500 babies were hospitalised with RSV throughout the study period, with the great majority being infants whose mothers did not receive the vaccination. This stark contrast emphasises the vaccine’s vital importance in protecting against serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a significant public health achievement, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.
Methodology and scope of study
The research examined birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection rates and hospital admissions. The substantial sample size and thorough nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology assessed actual clinical results rather than laboratory-based settings, providing real-world data of how the vaccine works when administered across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the threats
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during peak seasons.
The infection triggers inflammation deep within the lungs and airways, making it extremely challenging for affected infants to feed and breathe effectively. Parents commonly see their babies visibly struggling, their chests rising whilst they try to pull enough air into their compromised lungs. Whilst the majority of babies get better with clinical support, a limited though important number die from respiratory syncytial virus complications annually, making prevention through vaccination a essential public health priority for protecting the youngest and most vulnerable people in our communities.
- RSV causes lung inflammation, resulting in serious respiratory problems in infants
- Approximately half of newborns contract the infection in their first few months of life
- Symptoms range from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK infants require serious hospital care for RSV each year
- Small numbers of babies succumb to RSV related complications each year in the UK
Adoption rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have stressed the value of pregnant women getting their jab at the ideal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing matters greatly for ensuring newborns benefit from the strongest possible immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts recommend women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies via the placenta.
The communication from public health bodies stays clear: pregnant women should make a priority of vaccination during their final three months, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.
Regional disparities in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Certain regions have attained higher vaccination coverage among qualifying expectant mothers, whilst others continue working to boost understanding and access to the jab. These geographical variations reflect variations in healthcare infrastructure, communication strategies, and community involvement initiatives, though the national data demonstrates robust and reliable protection regardless of geographical location.
- NHS trusts deploying multiple messaging strategies to reach pregnant women
- Inconsistencies across regions in vaccination coverage levels across England require targeted improvement
- Local healthcare systems adapting programmes to align with local requirements and situations
Practical implications and parental perspectives
The vaccine’s outstanding effectiveness delivers real advantages for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the introduction of this preventative solution, the 80% decrease in admissions represents thousands of infants shielded from severe infection. Parents no longer face the upsetting situation of seeing their babies labour to breathe or struggle to eat, symptoms that define critical RSV illness. The vaccine has fundamentally shifted the landscape of neonatal lung health, offering expectant mothers a proactive tool to shield their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection caused devastating brain damage, the vaccine’s availability carries profound emotional significance. His mother’s promotion of the jab underscores the profound consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to pregnant women in their final trimester, changing what was once an predictable seasonal threat into a controllable health concern.